Allergy Immunotherapies Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2024 February 01
SKU : PH4050
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
loading
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Proceed to Buy
Request new version
FAQ’s
What is driving the growth of the allergy immunotherapy market?
The market is fueled by factors like rising allergy prevalence, increasing awareness, and advancements in immunotherapy technologies. Additionally, growing healthcare expenditure and R&D efforts further contribute to its expansion.
What are the different types of allergy immunotherapy treatments?
Two main types exist: Subcutaneous immunotherapy (SCIT) involves injections, while sublingual immunotherapy (SLIT) uses drops or tablets placed under the tongue. Both gradually desensitize the immune system to allergens.
Which region holds the largest market share in allergy immunotherapies?
Currently, Europe dominates the market due to factors like high allergy prevalence, strong industry presence, and active R&D initiatives. However, other regions like Asia Pacific are expected to see significant growth in the coming years.
Who are the key players in the allergy immunotherapy market?
Major players include Merck KGaA, Stallergenes Greer plc, Allergy Therapeutics, Mylan N.V., ASIT Biotech, DBV Technologies SA, and LETIPharma. These companies are actively engaged in product launches, acquisitions, and collaborations to drive market growth.